WO2023047340 - HIGH PURITY gRNA SYNTHESIS PROCESS
National phase entry:
Publication Number
WO/2023/047340
Publication Date
30.03.2023
International Application No.
PCT/IB2022/058998
International Filing Date
23.09.2022
Title **
[English]
HIGH PURITY gRNA SYNTHESIS PROCESS
[French]
PROCÉDÉ DE SYNTHÈSE D'ARNG DE HAUTE PURITÉ
Applicants **
CRISPR THERAPEUTICS AG
Baarerstrasse 14
6300 Zug, CH
Inventors
DAS, Rajat
610 Main Street
Cambridge, Massachusetts 02139, US
SANKARAN, Ganapathy
610 Main Street
Cambridge, Massachusetts 02139, US
Priority Data
63/248,102
24.09.2021
US
63/293,999
27.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 5317 | |
| EPO | Filing, Examination | 99187 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 30760 |
Total: 136466 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to methods, compositions and kits for synthesizing moderate length RNAs (mlRNAs, including gRNAs) by splint-mediated ligation of RNA fragments. The synthesis of moderate length RNAs can be followed by DNase treatment. In some embodiments, splint DNA oligonucleotides that are no longer than 32 nucleotides are used.[French]
La présente divulgation concerne des procédés, des compositions et des kits pour synthétiser des ARN de longueur modérée (ARNm, y compris les ARNg) par ligature de fragments d'ARN par "attelle" (splint). La synthèse d'ARN de longueur modérée peut être suivie d'un traitement à la DNase. Dans certains modes de réalisation, on utilise des oligonucléotides d'ADN splint ne dépassant pas 32 nucléotides.